Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients (Abemacare)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04681768 |
|
Recruitment Status :
Recruiting
First Posted : December 23, 2020
Last Update Posted : November 29, 2023
|
Sponsor:
Technical University of Munich
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Technical University of Munich
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2024 |
| Estimated Study Completion Date : | December 2024 |